Nektar Therapeutics (NKTR)

Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Nektar Therapeutics To Contact The Firm

Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Nektar Therapeutics (“Nektar” or the “Company”) (NASDAQ:NKTR) of the December 31, 2018 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

If you invested in Nektar stock or options between November 11, 2017 and October 2, 2018 and would like to discuss your legal rights, please fill out the form below. There is no cost or obligation to you. You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to 

The lawsuit has been filed in the U.S. District Court for the Northern District of California on behalf of all those who purchased Avalanche securities between November 11, 2017 and October 2, 2018 (the “Class Period”).  The case, Mulquin v. Nektar Therapeutics et al, No. 18-cv-06607 was filed on October 30, 2018, and has been assigned to Judge Haywood Stirling Gilliam, Jr.

The lawsuit focuses on whether the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) prior studies which attempted to pegylate IL-2 failed; (2) the extended half-life of NKTR-214, the Company’s lead immune-oncology candidate, was unlikely to result in efficacy and created additional high-dosing safety concerns; (3) NKTR-214 was less effective than IL-2 alone; and (4) the combination of NKTR-214 with nivolumab, another oncologic drug, has not yet demonstrated significant positive results.

Specifically, on October 1, 2018, Plainview published a report addressing the efficacy of NKTR-214, which the Company had previously touted as “a promising treatment for cancer, particularly in combination with checkpoint inhibitors.” The report asserted, among other things, that the core concept of Nektar’s plan to develop NKTR-214 has “never worked in practice.” The report also criticized Nektar’s decision to only disclose certain trial results as representing “an unprecedented level of data opacity.”

Following the publication of this report, Nektar’s share price fell from $60.96 per share on September 28, 2018 to a closing price of $55.33 on October 2, 2018—a $5.63 or a 9.24% drop over two trading days.

Contact us

Nektar Therapeutics (NKTR)

Loading captcha, please wait...

* The submission of this form does not create an attorney-client relationship.


Filed on 11/02/2018



685 Third Avenue 26th Floor

10017 New York, New York

Phone (212) 983-9330

Fax (212) 983-9331


Richard W. Gonnello Phone (212) 983-9330 Fax (212) 983-9331

Finding us

Our Offices

Our offices are nationwide. If you have any questions about a case or our firm, please contact us.

New York

685 Third Avenue 26th Floor
New York, New York 10017
(212) 983-9330
(877) 247-4292
(212) 983-9331


10866 Wilshire Boulevard Suite 1470
Los Angeles, California 90024
(424) 256-2884
(424) 256-2885


3828 Kennett Pike Suite 201
Wilmington, Delaware 19807
(302) 482-3182
(302) 482-3612


3975 Roswell Rd Suite A
Atlanta, Georgia 30342
(404) 847-0617
(404) 506-9534


1617 JFK Boulevard, Suite 1550
Philadelphia, Pennsylvania 19103
(215) 277-5770
(215) 277-5771

Faruqi & Faruqi office in New York, New York

Faruqi & Faruqi office in Los Angeles, California

Faruqi & Faruqi office in Wilmington, Delaware

Faruqi & Faruqi office in Atlanta, Georgia

Faruqi & Faruqi office in Philadelphia, Pennsylvania